Channel mix nirvana. It’s like a group of superheroes with all different strengths; working together to achieve the extraordinary. Deploy different channels to achieve different objectives.
As specialty therapies evolve and more treatment options for chronic and complex diseases become available, patients are seeking treatment options that are both effective and affordable.
As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.
Life sciences companies have an opportunity to craft a sales approach that resonates with clients, protects against future disruptions and stands out from the competition.
As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.
As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.
With an increase in digital technology being utilized as a strategic differentiator and business enabler in pharma, where is talent coming from?
With an increase in digital technology being utilized as a strategic differentiator and business enabler in pharma, where is talent coming from?
According to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA), America’s biopharmaceutical research companies are developing 435 new medicines to target 15 leading chronic conditions affecting the Medicare population.
While new regulatory requirements are often seen as a roadblock, they also present an opportunity to develop new and innovative solutions.
While new regulatory requirements are often seen as a roadblock, they also present an opportunity to develop new and innovative solutions.
A look at drug pricing and patents and the role for patents and how they are under attack.
While new regulatory requirements are often seen as a roadblock, they also present an opportunity to develop new and innovative solutions.
In medicines, as in life, the journey is just as important as the end result
The industry faces a problem of medical education and communication in regards to vaccinations.
The industry faces a problem of medical education and communication in regards to vaccinations.
The foundation of a strong rare disease marketing program must be built on the comprehensive knowledge of how the life-altering disease impacts all areas of a patient’s life.
The foundation of a strong rare disease marketing program must be built on the comprehensive knowledge of how the life-altering disease impacts all areas of a patient’s life.
A summary of the key impacts new law, California Consumer Privacy Act (CCPA), will have on business practices related to data flow in specialty pharma, and more.
Three changes manufacturers should consider in the wake of COVID-19.
A summary of the key impacts new law, California Consumer Privacy Act (CCPA), will have on business practices related to data flow in specialty pharma, and more.
Eight lessons to drive better outsourcing decisions.
AMCP Format Version 4.1 provides manufacturers with additional guidance to communicate evidence about potential new products or new uses to payers in a compliant fashion.
Sergio Ricardo Segovia Barbosa looks at Brazil’s growing competitiveness in the biopharma sector.